US Patent

US11160751 — Hematocrit modulation through needle assisted jet injection of testosterone

Method of Use · Assigned to Antares Pharma Inc · Expires 2034-10-07 · 8y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of delivering testosterone through needle-assisted jet injection for subcutaneous, intradermal, or intramuscular treatment.

USPTO Abstract

The present invention provides compositions and methods for treating a subject in need of treatment with testosterone, including introducing testosterone into the subject subcutaneously, intradermally, or intramuscularly, from a needle assisted jet injection device.

Drugs covered by this patent

testosterone-enanthate (TESTOSTERONE ENANTHATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2418`	—	testosterone-enanthate
`U-2418`	—	testosterone-enanthate
`U-2418`	—	testosterone-enanthate

Patent Metadata

Patent number: US11160751
Jurisdiction: US
Classification: Method of Use
Expires: 2034-10-07
Drug substance claim: No
Drug product claim: Yes
Assignee: Antares Pharma Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.